This is the authors' abstract. We don't add key points for this paper.
// Anatilde M. Gonzalez-Guerrico 1, * , Ingrid Espinoza 2, 3, * , Barbara Schroeder 1 , Cheol Hong Park 1 , Chandra Mohan KVP 1 , Ashwani Khurana 1 , Bruna Corominas-Faja 4, 5 , Elisabet Cuyàs 4, 5 , Tomás Alarcón 6, 7, 8, 9 , Celina Kleer 10 , Javier A. Menendez 4, 5 , Ruth Lupu 1, 11 1 Department of Laboratory Medicine and Pathology, Division of Experimental Pathology, Mayo Clinic, Rochester, MN, USA 2 Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA 3 Department of Biochemistry, University of Mississippi Medical Center, Jackson, MS, USA 4 ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain 5 Molecular Oncology Group, Girona Biomedical Research Institute (IDIBGI), Girona, Spain 6 Computational and Mathematical Biology Research Group, Centre de Recerca Matemàtica (CRM), Barcelona, Spain 7 Departament de Matemàtiques, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain 8 ICREA (Institució Catalana d’Estudis i Recerca Avançats), Barcelona, Spain 9 Barcelona Graduate School of Mathematics (BGSMath), Barcelona, Spain 10 Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA 11 Mayo Clinic Cancer Center, Rochester, MN, USA * These authors contributed equally to this work Correspondence to: Ruth Lupu, email: lupu.ruth@mayo.edu Javier A. Menendez, email: jmenendez@idibgi.org , jmenendez@iconcologia.net Keywords: fatty acid synthase, lipogenesis, cancer, tumor reversion, phenotype Received: February 26, 2016 Accepted: May 04, 2016 Published: May 18, 2016 ABSTRACT The correction of specific signaling defects can reverse the oncogenic phenotype of tumor cells by acting in a dominant manner over the cancer genome. Unfortunately, there have been very few successful attempts at identifying the primary cues that could redirect malignant tissues to a normal phenotype. Here we show that suppression of the lipogenic enzyme fatty acid synthase (FASN) leads to stable reversion of the malignant phenotype and normalizes differentiation in a model of breast cancer (BC) progression. FASN knockdown dramatically reduced tumorigenicity of BC cells and restored tissue architecture, which was reminiscent of normal ductal-like structures in the mammary gland. Loss of FASN signaling was sufficient to direct tumors to a reversed phenotype that was near normal when considering the development of polarized growth-arrested acinar-like structure similar to those formed by nonmalignant breast cells in a 3D reconstituted basement membrane in vitro . This process, in vivo , resulted in a low proliferation index, mesenchymal-epithelial transition, and shut-off of the angiogenic switch in FASN-depleted BC cells orthotopically implanted into mammary fat pads. The role of FASN as a negative regulator of correct breast tissue architecture and terminal epithelial cell differentiation was dominant over the malignant phenotype of tumor cells possessing multiple cancer-driving genetic lesions as it remained stable during the course of serial in vivo passage of orthotopic tumor-derived cells. Transient knockdown of FASN suppressed hallmark structural and cytosolic/secretive proteins (vimentin, N-cadherin, fibronectin) in a model of EMT-induced cancer stem cells (CSC). Indirect pharmacological inhibition of FASN promoted a phenotypic switch from basal- to luminal-like tumorsphere architectures with reduced intrasphere heterogeneity. The fact that sole correction of exacerbated lipogenesis can stably reprogram cancer cells back to normal-like tissue architectures might open a new avenue to chronically restrain BC progression by using FASN-based differentiation therapies.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
González-Guerrico et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: